STAGE IV OVARIAN CANCER AJCC V8

This study tests a combination of two targeted drugs, palbociclib and binimetinib, in people with cancers that have RAS mutations (like certain ovarian and pancreatic cancers). The goal is to see if the combo can slow tumor growth better than one drug alone. About 199 adults will…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors that have spread. The main goal is to find the safes…

This early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…

This early-phase trial is testing the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. The goal is to see if taking olaparib for two cycles can safely shrink tumors and stop them from growing. Olap…

This early-phase trial tests a new drug (BAY 1895344) combined with standard chemotherapy in people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, bladder, …

This study tests the drug pembrolizumab in 21 adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. Pembrolizumab is a type of immunotherapy that helps the immune system…

This study tests whether the hormone therapy letrozole alone works as well as chemotherapy plus letrozole for people with stage II to IV low-grade serous ovarian, fallopian tube, or peritoneal cancer. Letrozole lowers estrogen, which can slow tumor growth. The trial aims to find …

This early-phase study tested adding the experimental drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) for people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to find the safest dose and check for side effec…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests an online program called Day by Day to help women with stage III or IV gynecologic cancer manage fears about their cancer growing or coming back. About 23 women will use the program and report how helpful it is. The goal is to see if the program is easy to use an…

This study looks at whether doctors can consistently measure the chemotherapy drug paclitaxel in the blood of cancer patients. The goal is to see if this could help adjust doses to kill cancer while reducing nerve damage, a common side effect. About 22 adults with various solid t…

This study was designed to see if an online mental health program could help women with advanced gynecologic or breast cancer manage their fear of the cancer returning or getting worse. The program would have been compared to standard educational materials. However, the trial was…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will store and study these samples over time to learn how cancer changes and why some treatments stop working. The goal is to improve future …